Polytrauma Fellowship Seminar Series

Upcoming Talks

Prior Talks

November 2021

The November 2021, VA Polytrauma Fellowship Seminar featured Dr.  Marc A Silva, PhD from the James A. Haley Veterans’ Hospital. 

Dr. Silva's talk was titled " Improving Sleep Apnea Treatment" a copy of his slides are available to download. 

Dr. Silva's talk excellent talk covered:

  1. Traumatic brain injury (TBI) and obstructive sleep apnea (OSA)
  2. The characteristics of OSA
  3. Frontline and alternative OSA treatments
  4. The health benefits OSA treatment
  5. Define persistent airway pressure (PAP) adherence and identify rates of nonadherence in veterans with TBI
  6. Demonstrate awareness of interventions designed to improve OSA treatment adherence

October 2021

The October 2021, VA Polytrauma Fellowship Seminar featured Flora Hammond, MD from the Indiana University School of Medicine.

Dr. Hammond talk was titled  "Evidence-based Management of Brain Injury Irritability and Aggression" a copy of her slides are available to download. Her excellent talk covered identifying:

  1. Factors believed to contribute to irritability and aggression after TBI
  2. Pharmacologic interventions that may reduce irritability and aggression following TBI
  3. Non-pharmacologic interventions that may reduce irritability and aggression following TBI

September 2021

The September 2021 Polytrauma Seminar featured Dr. Kirsten Cherian and Dr. John Coetzee.

They presented on a study that they are currently conducting: An observational pre-post study evaluating safety of a naturally occurring psychoactive compound of the tabernanthe iboga plant.

The focus of the study is on individuals with a history of TBI, particularly Special Operations Veterans who have had multiple blast exposures.

Many Special Operations Veterans experience a plethora of health and psychiatric difficulties following their service. Many of them have not received benefit from the treatments available to them.

Ibogaine has shown promise in facilitating significant improvement in multiple symptoms including cognitive, psychological, and physical. They are working to identify a safety profile for this substance, that is currently Schedule 1 in the US, through psychological and neuropsychological testing, and functional imaging.

Their talk titled "Safety Profile Study of Ibogaine for Treating Chronic TBI Symptoms" is available to watch.